- Home
- HAYW vs MTSR Comparison
HAYW vs MTSR Comparison
Compare HAYW & MTSR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HAYW
- MTSR
- Stock Information
- Founded
- HAYW 1925
- MTSR 2022
- Country
- HAYW United States
- MTSR United States
- Employees
- HAYW N/A
- MTSR N/A
- Industry
- HAYW Electronic Components
- MTSR
- Sector
- HAYW Technology
- MTSR
- Exchange
- HAYW Nasdaq
- MTSR NYSE
- Market Cap
- HAYW 2.9B
- MTSR 3.0B
- IPO Year
- HAYW 2021
- MTSR 2025
- Fundamental
- Price
- HAYW $14.98
- MTSR $39.47
- Analyst Decision
- HAYW Hold
- MTSR Strong Buy
- Analyst Count
- HAYW 5
- MTSR 6
- Target Price
- HAYW $16.83
- MTSR $55.25
- AVG Volume (30 Days)
- HAYW 2.0M
- MTSR 870.9K
- Earning Date
- HAYW 07-30-2025
- MTSR 08-26-2025
- Dividend Yield
- HAYW N/A
- MTSR N/A
- EPS Growth
- HAYW 51.32
- MTSR N/A
- EPS
- HAYW 0.56
- MTSR N/A
- Revenue
- HAYW $1,067,878,000.00
- MTSR N/A
- Revenue This Year
- HAYW $5.27
- MTSR N/A
- Revenue Next Year
- HAYW $5.51
- MTSR N/A
- P/E Ratio
- HAYW $26.66
- MTSR N/A
- Revenue Growth
- HAYW 7.34
- MTSR N/A
- 52 Week Low
- HAYW $11.10
- MTSR $12.30
- 52 Week High
- HAYW $16.87
- MTSR $40.47
- Technical
- Relative Strength Index (RSI)
- HAYW 65.25
- MTSR N/A
- Support Level
- HAYW $14.00
- MTSR N/A
- Resistance Level
- HAYW $15.33
- MTSR N/A
- Average True Range (ATR)
- HAYW 0.40
- MTSR 0.00
- MACD
- HAYW 0.13
- MTSR 0.00
- Stochastic Oscillator
- HAYW 83.33
- MTSR 0.00
About HAYW Hayward Holdings Inc.
Hayward Holdings is a leading manufacturer of energy-efficient swimming pool equipment and pool automation systems. The company offers a wide range of pool equipment, including pumps, filters, heaters, LED lights, and sanitization. Headquartered in Charlotte, North Carolina, the company has around 2,000 full-time employees. Hayward generated approximately $1.1 billion in revenue in 2024.
About MTSR METSERA INC
Metsera Inc is a clinical-stage biotechnology company developing next-generation injectable and oral nutrient-stimulated hormone (NuSH) analog peptides to treat obesity, overweight, and related conditions. The Company has developed and is implementing proprietary methods and platform technologies to advance a broad, scalable, and combinable portfolio of injectable and oral NuSH analog peptides with the potential to address not only the limitations of approved therapies but also many of the anticipated limitations of next-generation therapies in development. The Company uses its proprietary MINT peptide library of NuSH analog peptides alongside its Half-life Augmentation by Lipid Optimization half-life extending platform.